NIH supports milestone-driven Down syndrome clinical trial development with up to two years of planning and a possible three-year clinical trial phase, for a maximum of five years.
NIH supports exploratory and developmental research addressing critical needs in Down syndrome to improve health and quality of life; clinical trials are not allowed.
NIH supports transformative research on Down syndrome and co-occurring conditions by individual scientists or teams, with no preliminary data required and no clinical trials allowed.
This grant invites researchers to submit biospecimens for omics analysis to study Down syndrome, generating shared data to advance understanding of related health conditions; no direct funding is provided.
NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NIH's R21 grant supports early-stage, high-risk clinical trial research with potential for breakthroughs in biomedical, behavioral, or clinical fields.